findmyKOL
Clinical trialNCT00033462CompletedPhase 2Interventional

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

SponsorNational Cancer Institute (NCI)Enrollment78Adult Primary Cholangiocellular CarcinomaAdult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerCholangiocarcinoma of the Extrahepatic Bile DuctCholangiocarcinoma of the GallbladderLocalized Unresectable Adult Primary Liver Cancer+5 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Mayo Clinic

    Rochester, Minnesota, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Mar 2002
Primary completion
30 Nov 2006
Completion
—
Last update posted
4 Jun 2013
Registered enrollment
78
Registry id
NCT00033462
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.